Sodium dicarboxylate cotransporter-1 expression in renal tissues and its role in rat experimental nephrolithiasis

Journal of Nephrology

Volumn 17, Issue 1, 2004, Pages 34-42

  He, Yani ^a   Chen, Xiangmei ^a   Yu, Zhiheng ^a   Wu, Di ^a   Lv, Yang ^a   Shi, Suozhu ^a   Zhu, Hanyu ^a  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

Citrate; Experimental; Nephrolithiasis; Sodium dicarboxylate cotransporter; Treatment

Indexed keywords

CALCIUM OXALATE; CITRATE POTASSIUM; CITRIC ACID; COTRANSPORTER; ETHYLENE GLYCOL; MESSENGER RNA; OXALIC ACID; SODIUM DICARBOXYLATE COTRANSPORTER 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM URINE LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MALE; NEPHROLITHIASIS; NONHUMAN; NORTHERN BLOTTING; QUANTITATIVE ANALYSIS; RAT; SODIUM TRANSPORT; STATISTICAL ANALYSIS; URINALYSIS; URINARY EXCRETION;

ANIMALS; BLOTTING, NORTHERN; CALCIUM; CITRIC ACID; DICARBOXYLIC ACID TRANSPORTERS; EPITHELIUM; ETHYLENE GLYCOL; HYDROGEN-ION CONCENTRATION; IMMUNOHISTOCHEMISTRY; KIDNEY CALCULI; KIDNEY TUBULES, PROXIMAL; MALE; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; OXALIC ACID; POTASSIUM CITRATE; RATS; RATS, WISTAR; RNA, MESSENGER; SYMPORTERS;

EID: 1842555192     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pak CY. Kidney stones. Lancet 1998; 351: 1797-801.
2. Serio A, Fraioli A. Epidemiology of nephrolithiasis. Nephron 1999; 81 (suppl 1): S26-30.
3. Bushinsky DA. Nephrolithiasis. J Am Soc Nephrol 1998; 9: 917-24.
4. Yagisawa T, Chandhoke PS, Fan J. Metabolic risk factors in patients with first-time and recurrent stone formations as determined by comprehensive metabolic evaluation. Urology 1998; 52: 750-55.
5. Hamm LL, Hering-Smith KS. Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 2002; 31: 885-93.
6. Fegan J, Khan R, Poindexter J, Pak CY. Gastrointestinal citrate absorption in nephrolithiasis. J Urol 1992; 147: 1212-4.
7. Yagisawa T, Kobayashi C, Hayashi T, Yoshida A, Toma H. Contributory metabolic factors in the development of nephrolithiasis in patients with medullary sponge kidney. Am J Kidney Dis 2001; 37: 1140-3.
8. Cupisti A, Morelli E, Lupetti S, Meola M, Barsotti G. Low urine citrate excretion as main risk factor for recurrent calcium oxalate nephrolithiasis in males. Nephron 1992; 61: 73-6.
9. Kok DJ, Papapoulos SE, Bijvoet OL. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers. Lancet 1986; 1: 1056-8.
10. Hojgaard I, Tiselius HG. The effects of citrate and urinary macromolecules on the aggregation of hydroxyapatite crystals in solutions with a composition similar to that in the distal tubule. Urol Res 1998; 26: 89-95.
11. Ryall RL. Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol 1997; 15: 155-64.
12. Barcelo P, Wuhl O, Servitge E, Rousaud A, Pak CY. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 1993; 150: 1761-4.
13. Ebisuno S, Morimoto S, Yoshida T, Fukatani T, Yasukawa S, Ohkawa T. Effect of dietary calcium and magnesium on experimental renal tubular deposition of calcium oxalate crystal induced by ethylene glycol administration and its prevention with phytin and citrate. Urol Int 1987; 42: 330-7.
14. Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 1997; 158: 2069-73.
15. Hamm LL. Renal handling of citrate. Kidney Int 1990; 38: 728-35.
16. Pajor AM. Citrate transport by the kidney and intestine. Semin Nephrol 1999; 19: 195-200.
17. + /dicarboxylate transporter. Am J Physiol 1998; 275: F298-305.
18. +/dicarboxylate transporter. J Biol Chem 1998; 273: 20972-81.
19. Tompkins D, Toffaletti J. Enzymic determination of citrate in serumDand urine, with use of the Worthington "ULtrafree" device. Clin Chem 1982; 28: 192-5.
20. Berckmans RJ, Boer P. An inexpensive method for sensitive enzymatic determination of oxalate in urine and plasma. Clin Chem 1988; 34: 1451-5.
21. +/dicarboxylate co-transporter 1 as fusion protein in E. coli and the production of its antibody. Chin J Biochem Mol Biol 2002; 18: 356-60.
22. Howard JE, Thomas WC. Some observations on rachitic rat cartilage of probable significance in the etiology of renal calculi. Trans Am Clin Climatol Assoc 1958; 70: 94-102.
23. Marangella M, Vitale C, Manganaro M, Cosseddu D, Martini C, Petrarulo M, Linari F. Renal handling of citrate in chronic renal insufficiency. Nephron 1991; 57: 439-43.
24. Aruga S, Wehrli S, Kaissling B, Moe OW, Preisig PA, Pajor AM, Alpern RJ. Chronic metabolic acidosis (CMA) increase renal cortical NaDC-1 mRNA and protein abundance in rats. Kidney Int 2000; 58: 206-15.
25. Khan SR. Animal models of kidney stone formation: An analysis. World J Urol 1997; 15: 236-43.
26. Wright SH, Wunz TM. Succinate and citrate transport in renal basolateral and brush-border membranes. Am J Physiol 1987; 253: F432-9.
27. Levi M, McDonald LA, Preisig PA, Alpern RJ. Chronic K depletion stimulates rat renal brush-border membrane Na-citrate cotransporter. Am J Physiol 1991; 261: F767-73.
28. Wu D, Chen XM. The expression of sodium/dicarboxylate cotransporters in kidney of rats with experimental metabolic acidosis. Acta Physiologica Sinica 2000; 1: 55-7.
29. +/ dicarboxylate co-transporter expression in rat nephrolithiasis induced by lithogenic agent and the prevention of potassium bicarbonate. Acta Academiae Medicinae Militaris Tertiae 2003; 25: 985-9.